Targeting the endocannabinoid system to treat diseases using pharmacology and medicinal chemistry approaches, Artiam Bio is initially focused on non-alcoholic and alcoholic liver diseases, Prader Willi syndrome and cannabis use disorder. Potential end-user markets are diverse ranging from Congenital and Genetic Diseases, Nutritional and Metabolic Disorders, to Digestive System and Gastrointestinal Diseases
